JPRN-jRCT2080224681已完成1 期
An open label, Phase I study of BI 836880 monotherapy and combination therapy of BI 836880 and BI 754091 in Japanese patients with advanced solid tumours
ippon Boehringer Ingelheim Co., Ltd.0 个研究点目标入组 21 人开始时间: 2019年5月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Signed and dated written informed consent in accordance with International Council on Harmonisation (ICH) Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
- •2. Patients with a confirmed diagnosis of advanced, unresectable, and/or metastatic solid tumours (any type).
排除标准
- •1. Known hypersensitivity to the trial drugs or their excipients
- •2. Known HIV, HBV, or HCV infection
- •3. History of severe hypersensitivity reactions to other mAbs
研究者
相似试验
已完成
1 期
This study aims to find a safe and effective dose of BI 754091. The study also aims to find safe and effective doses of BI 754091 and BI 754111 in combination. This study is done in Asian patients with different types of cancerJPRN-jRCT2080223817Boehringer Ingelheim164
进行中（未招募）
1 期
A study to test different doses of BI 765063 alone and in combination with BI 754091 in Japanese patients with different types of advanced cancer (solid tumors)JPRN-jRCT2031200355akajima Michiko36
已完成
不适用
An open label phase I dose finding study of BI 853520 administered orally in a continuous dosing schedule in patients with various advanced or metastatic non-hematologic malignanciessolid tumours10027655cancerNL-OMON39828Boehringer Ingelheim45
已完成
1 期
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced CancerNeoplasmsNCT03972150Boehringer Ingelheim21
已完成
1 期
A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic CancerNeoplasmsNCT01335269Boehringer Ingelheim96